{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:34:15Z","timestamp":1793212455682,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1053\/j.ajkd.2026.06.018","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:22:21Z","timestamp":1790097741000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Perspective on the Role of Nephrologists in the Cardiovascular-Kidney-Metabolic Syndrome"],"prefix":"10.1053","author":[{"given":"Vikas S.","family":"Sridhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-8401","authenticated-orcid":false,"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2026.06.018_bib1","first-page":"336","article-title":"Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine","volume":"1","author":"Bright","year":"1836","journal-title":"Guy\u2019s Hosp Rep"},{"issue":"12","key":"10.1053\/j.ajkd.2026.06.018_bib2","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2026.06.018_bib3","article-title":"Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease","volume":"126","author":"Liu","year":"2021","journal-title":"Metabolism"},{"issue":"10","key":"10.1053\/j.ajkd.2026.06.018_bib4","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"issue":"13","key":"10.1053\/j.ajkd.2026.06.018_bib5","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Writing Group for the CKD Prognosis Consortium","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1053\/j.ajkd.2026.06.018_bib6","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1053\/j.ajkd.2026.06.018_bib7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"20","key":"10.1053\/j.ajkd.2026.06.018_bib8","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a Presidential Advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1053\/j.ajkd.2026.06.018_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","article-title":"The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"99","author":"Shlipak","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2026.06.018_bib10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ekir.2020.11.039","article-title":"Adherence to the Kidney Disease: Improving Global Outcomes CKD Guideline in nephrology practice across countries","volume":"6","author":"Stengel","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2026.06.018_bib11","doi-asserted-by":"crossref","first-page":"R690","DOI":"10.1152\/ajpregu.00237.2020","article-title":"Renal functional reserve: from physiological phenomenon to clinical biomarker and beyond","volume":"319","author":"Jufar","year":"2020","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"4","key":"10.1053\/j.ajkd.2026.06.018_bib12","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.athoracsur.2017.12.034","article-title":"Preoperative renal functional reserve predicts risk of acute kidney injury after cardiac operation","volume":"105","author":"Husain-Syed","year":"2018","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"10.1053\/j.ajkd.2026.06.018_bib13","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s12325-023-02482-5","article-title":"Patient management and clinical outcomes associated with a recorded diagnosis of stage 3 chronic kidney disease: the REVEAL-CKD Study","volume":"40","author":"Tangri","year":"2023","journal-title":"Adv Ther"},{"issue":"4 suppl","key":"10.1053\/j.ajkd.2026.06.018_bib14","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2026.06.018_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jcjd.2025.01.004","article-title":"Chronic kidney disease in diabetes: a clinical practice guideline","volume":"49","author":"Tobe","year":"2025","journal-title":"Can J Diabetes"},{"key":"10.1053\/j.ajkd.2026.06.018_bib16","series-title":"Care and referral of adult patients with reduced renal function: recommendations from the Canadian Society of Nephrology (CSN)","year":"2014"},{"issue":"6","key":"10.1053\/j.ajkd.2026.06.018_bib17","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"10.1053\/j.ajkd.2026.06.018_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.45309","article-title":"Prevalence of cardiovascular-kidney-metabolic syndrome stages by social determinants of health","volume":"7","author":"Zhu","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1053\/j.ajkd.2026.06.018_bib19","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1681\/ASN.0000000658","article-title":"Global burden of the key components of cardiovascular-kidney-metabolic syndrome","volume":"36","author":"Xie","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"special 1","key":"10.1053\/j.ajkd.2026.06.018_bib20","article-title":"Cardio-kidney-metabolic (CKM) framework: a nephrologist\u2019s perspective","volume":"70","author":"Moura","year":"2025","journal-title":"Arch Endocrinol Metab"},{"issue":"23","key":"10.1053\/j.ajkd.2026.06.018_bib21","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C Collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"issue":"2","key":"10.1053\/j.ajkd.2026.06.018_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1053\/j.ajkd.2026.06.018_bib23","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"10365","key":"10.1053\/j.ajkd.2026.06.018_bib24","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"10.1053\/j.ajkd.2026.06.018_bib25","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/ndt\/gfaf046","article-title":"Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease","volume":"40","author":"Bakker","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2026.06.018_bib26","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/TP.0000000000003919","article-title":"Cardiometabolic and kidney protection in kidney transplant recipients with diabetes: mechanisms, clinical applications, and summary of clinical trials","volume":"106","author":"Sridhar","year":"2022","journal-title":"Transplantation"},{"issue":"8","key":"10.1053\/j.ajkd.2026.06.018_bib27","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1111\/dom.15112","article-title":"Kidney protection with canagliflozin: a combined analysis of the randomized CANVAS program and CREDENCE trials","volume":"25","author":"Sridhar","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1053\/j.ajkd.2026.06.018_bib28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.124.069382","article-title":"Timing of cardio-kidney protection with SGLT2 inhibitors: insights from 4 large-scale placebo-controlled outcome trials","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2026.06.018_bib29","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/ndt\/gfae216","article-title":"Upcoming drug targets for kidney protective effects in chronic kidney disease","volume":"40","author":"Nardone","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"10504","key":"10.1053\/j.ajkd.2026.06.018_bib30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","article-title":"Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial","volume":"406","author":"Walsh","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ajkd.2026.06.018_bib31","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ndt\/gfac283","article-title":"Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease","volume":"38","author":"Nee","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2026.06.018_bib32","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.9778\/cmajo.20210281","article-title":"Use of sodium-glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation","volume":"11","author":"Lau","year":"2023","journal-title":"CMAJ Open"},{"key":"10.1053\/j.ajkd.2026.06.018_bib33","article-title":"Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data","volume":"43","author":"Neuen","year":"2024","journal-title":"Lancet Reg Health West Pac"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263862601125X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263862601125X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:53:36Z","timestamp":1793210016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027263862601125X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"alternative-id":["S027263862601125X"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.06.018","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Perspective on the Role of Nephrologists in the Cardiovascular-Kidney-Metabolic Syndrome","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}